ACTRN12610000515099
Completed
Phase 4
A randomised, controlled trial to investigate the real-life use of the Vannair SMART regime in adult asthma (the SMART study)
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Medical Research Institute of New Zealand
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. A doctor's diagnosis of asthma; 2\. A current prescription for inhaled corticosteroid (ICS) medications; 3\. No change in the dose of ICS in the last month; 4\. An asthma exacerbation in the previous year where the patient presented to a General Practitioner or Emergency Department and was prescribed a course of oral steroids and/or received a spacer/nebuliser\-delivered bronchodilator and patients who self\-administered prednisone for asthma for at least 3 days.
Exclusion Criteria
- •1\. Onset of respiratory symptoms after the age of 40 years in current or ex\-smokers with a greater than or equal to 10 pack years smoking history; 2\. use of an at\-home nebuliser (unless patients agree to withhold nebuliser use for the study duration); 3\. treatment with oral prednisone in the previous 4 weeks; 4\. diagnosis of Chronic Obstructive Pulmonary Disease (COPD), interstitial lung disease or bronchiectasis; 5\. unsuitable cardiovascular or other medical history, or any other safety concern at the investigator's discretion; 6\. unable or unwillling to give consent to participate, to follow the study requirements and/or to change from current asthma treatment regime.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder or bipolar disorder type I and II (currently in a depressive episode)MedDRA version: 20.0Level: HLTClassification code: 10039620Term: Schizoaffective and schizophreniform disorders Class: 10037175MedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175MedDRA version: 20.0Level: PTClassification code: 10039626Term: Schizophrenia Class: 100000004873MedDRA version: 21.1Level: LLTClassification code: 10004936Term: Bipolar depression Class: 10037175Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]CTIS2022-502185-24-00niversity Medical Center Utrecht1,254
Active, not recruiting
Phase 1
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Bipolar depressionMedDRA version: 21.1Level: LLTClassification code: 10004936Term: Bipolar depression Class: 10037175Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]CTIS2023-506605-19-00niversitair Medisch Centrum Utrecht423
Active, not recruiting
Phase 1
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Major depressive disorderMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]CTIS2023-506617-21-00niversitair Medisch Centrum Utrecht418
Active, not recruiting
Phase 4
A clinical study to investigate whether third-line treatments work better as a second-line treatment for people diagnosed with schizophreniaSchizophrenia, schizoaffective disorder or schizophreniform disorderMental and Behavioural DisordersISRCTN83479057niversity Medical Center Utrecht418
Recruiting
Phase 1
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.schizophrenia, schizoaffective disorder, schizophrenifom disorderMedDRA version: 21.1Level: PTClassification code: 10039647Term: Schizophreniform disorder Class: 100000004873MedDRA version: 20.0Level: PTClassification code: 10039626Term: Schizophrenia Class: 100000004873MedDRA version: 21.1Level: PTClassification code: 10039621Term: Schizoaffective disorder Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]CTIS2023-506602-39-00niversitair Medisch Centrum Utrecht418